Technical Analysis for ELTX - Elicio Therapeutics, Inc.

Grade Last Price % Change Price Change
C 4.59 7.75% 0.33
ELTX closed up 7.75 percent on Friday, November 1, 2024, on 51 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Nov 7
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 7.75%
50 DMA Resistance Bearish 7.75%
Lower Bollinger Band Walk Weakness 7.75%
Gapped Up Strength 7.75%
Oversold Stochastic Weakness 7.75%

   Recent Intraday Alerts

Alert Time
Rose Above 50 DMA about 19 hours ago
Rose Above 10 DMA about 19 hours ago
Possible NR7 about 19 hours ago
Possible Inside Day about 19 hours ago
Up 3% about 21 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Elicio Therapeutics, Inc. Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, to treat or prevent a range of diseases; ELI-003 for cancers involving an ALK mutation; ELI-011 for hematological cancers; ELI-005, a product for the prevention of COVID-19; and ELI-002 7P (AMPLIFY-7P), a vaccine for mutated solid tumors. The company's AMP platform enables to develop differentiated treatment modalities including therapeutic vaccines, adjuvants, and cell therapy AMPlifiers. The company was formerly known as VEDANTRA PHARMACEUTICALS, INC. and changed its name to Elicio Therapeutics Inc. on September 18, 2019. The company was incorporated in 2011 and is headquartered in Boston, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Disease Solid Tumors Treatment Of Cancer Cell Therapy Immunotherapies Vaccines Vaccination Virology Hematological Cancers Anaplastic Lymphoma Kinase

Is ELTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.45
52 Week Low 2.96
Average Volume 15,623
200-Day Moving Average 5.82
50-Day Moving Average 4.54
20-Day Moving Average 4.64
10-Day Moving Average 4.55
Average True Range 0.34
RSI (14) 49.49
ADX 17.49
+DI 17.18
-DI 19.36
Chandelier Exit (Long, 3 ATRs) 3.99
Chandelier Exit (Short, 3 ATRs) 5.06
Upper Bollinger Bands 5.08
Lower Bollinger Band 4.20
Percent B (%b) 0.44
BandWidth 19.10
MACD Line -0.08
MACD Signal Line -0.03
MACD Histogram -0.0493
Fundamentals Value
Market Cap 44.09 Million
Num Shares 9.61 Million
EPS -3.93
Price-to-Earnings (P/E) Ratio -1.17
Price-to-Sales 0.00
Price-to-Book 3.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.98
Resistance 3 (R3) 4.96 4.80 4.92
Resistance 2 (R2) 4.80 4.70 4.82 4.89
Resistance 1 (R1) 4.70 4.64 4.75 4.72 4.87
Pivot Point 4.54 4.54 4.57 4.56 4.54
Support 1 (S1) 4.44 4.44 4.49 4.46 4.31
Support 2 (S2) 4.28 4.38 4.30 4.29
Support 3 (S3) 4.18 4.28 4.27
Support 4 (S4) 4.20